Objective: The aim of this study was to assess the relationship of the timing of hormone therapy (HT) use with angiographic coronary artery disease (CAD) and cardiovascular disease (CVD) events in women with natural versus surgical menopause.
CAD. Exogenous reproductive hormones have also been proposed to play a role in CAD. 4 In animal oophorectomy models, hormone therapy (HT) has antiatherosclerotic effects when initiated early after oophorectomy, 5 and observational epidemiological studies in humans have demonstrated protective effects for CAD among postmenopausal HT users. 6, 7 Clinical trials, however, have demonstrated overall no benefit and early adverse effects in women after menopause randomized to a variety of forms of HT, using angiographic 8, 9 or clinical outcomes. 10<12 This discrepancy has called into question the validity of the endogenous estrogen protection hypothesis, as well as the prior animal and human epidemiological exogenous HT studies.
Recent data have shed light on this controversy. In the observational Nurses' Health Study, younger women without coronary heart disease had a reduction of adverse events with HT, 6 but older women with known disease had an initial increase in adverse events followed by a reduction after several years of treatment, 13 which was similar to what was seen with older women in the Women's Health Initiative (WHI) trials. In the pooled WHI trials, women who started HT within 10 years of menopause had less relative risk for adverse events compared with those who started HT greater than 10 years from menopause. 14 Pooled data from randomized trials including the WHI found a statistical trend in lower relative risk, suggesting that HT when started closer to the age of menopause may reduce adverse events compared with HT started at an older age. 14, 15 Prior studies have also not been able to assess directly the putative mechanism of HT benefit, for example, coronary atherosclerosis.
The Women's Ischemia Syndrome Evaluation (WISE) is a prospective, multicenter National Heart, Lung, and Blood InstituteYsponsored study designed to explore female-specific CVD pathophysiology in a large sample of women undergoing coronary angiography for suspected ischemic heart disease. 16 We undertook a detailed study to examine the relationship between the timing and type of menopause and the timing of HT use with CAD, measured by quantitative coronary angiography and prospective adverse CVD events, to shed additional light on this controversy.
METHODS
Women undergoing coronary angiography because of suspected ischemia underwent a one-time baseline evaluation that included collection of demographic, medical history, detailed reproductive history and exogenous hormone use, and psychosocial and symptom data from 1998 to 2002, as described previously 16 (cross-sectional phase). These women have been followed annually for major adverse CVD events for a median of 6 years (prospective phase). Blood for reproductive hormone determinations was drawn at baseline after an overnight fast in close temporal proximity to the WISE testing. The study was approved by all involved sites' institutional review boards.
Reproductive status questionnaire
The WISE reproductive status algorithm has been validated to be an accurate assessment of menopause status and current HT use using both a detailed questionnaire and blood reproductive hormone levels. 17 The WISE reproductive status questionnaire includes a detailed history of menarche, date of last menstrual period, current and prior menstrual cycling patterns, prior reproductive events (pregnancy, hysterectomy, and unilateral and bilateral oophorectomy), current and prior perimenopausal symptoms, and current and prior oral contraceptive or HT use. 17 Reproductive hormone levels were assessed using validated steroid and protein assay methods for total estradiol, bioavailable estradiol, estrone, progesterone, follicle-stimulating hormone, and luteinizing hormone. 18 Documentation of the type of gynecological surgery was obtained when the blood reproductive hormone levels were not consistent with the reported status during an expert consensus review for menopause status determination.
A total of 654 postmenopausal WISE women were included in the current analysis. Among those without a history of hysterectomy or oophorectomy, the mean age of the last menstrual cycle was 49 years in smokers compared with 51 years in nonsmokers; thus, we imputed these menopause ages for cessation of ovarian cycling in women with a premenopausal hysterectomy (with and without unilateral oophorectomy; n = 27). Because 95% of women are postmenopausal by age 55 years, 19 we used a conservative threshold of 55 years to define the initiation of HT use before versus after menopause. Surgical menopause was defined as bilateral oophorectomy performed within less than 1 year after the last menstrual period.
Measurement of CAD
Coronary angiography was assessed at baseline by a core laboratory (blinded to historical or clinical data) used in previous National Heart, Lung, and Blood InstituteYsponsored multicenter trials. 20 Measurements included quantitative assessment of the presence of obstructive CAD, defined as 70% or more luminal diameter stenosis in one or more epicardial coronary artery, and the WISE CAD severity score, using previously published methods. 20 The WISE CAD severity score was based on percent stenosis adjusted for any complete collateral vessels, with the possible range of score being 5 (no detectable stenosis) to 100 (multiple severe lesions), and the actual range in the WISE was 5 to 78.
Adverse cardiovascular events
Major adverse CVD events were defined as CVD-related mortality, myocardial infarction, congestive heart failure, or stroke. Women were contacted by telephone annually by experienced study coordinators completing a scripted interview about adverse CVD events or hospitalizations up to 9 years (median, 6.0 [interquartile range, 3.8-7.1]). If a woman was no longer living, we obtained a death certificate where available, records of any related CVD hospitalizations during the preceding follow-up time period, and/or description by a primary relative regarding the circumstances surrounding the death. The cause of death was reviewed by two cardiologist investigators blinded to the clinical and angiographic data; a third reviewer was used in discrepant death classification. For nonfatal major events (myocardial infarction, stroke, or heart failure), one WISE clinical site examined the hospital and clinic records from 113 WISE women, and only 1.8% of the self-reported events required reclassification, suggesting high accuracy in self-reported morbidity rates.
Statistical methods
Values are expressed as raw means T SDs or percentages as indicated. Because of the strong association of age with predictors and outcomes, we age adjusted all P values and odds ratios (ORs) and 95% CIs, as well as A coefficients and standard errors throughout this report. We used a logistic regression when comparing women with obstructive CAD versus those without obstructive CAD (Tables 2 and 3) or women with natural versus surgical menopause ( Table 4 ). We used a linear regression when the dependent variable was the continuous CAD severity score rather than the dichotomous variable of obstructive CAD presence. For Table 5 , we performed a twofactor analysis of variance that assessed the demographic and health risk variables according to HT use and menopause type (surgical vs natural), as well as their interaction terms, with P values again adjusted for age ( Table 5) .
To assess the degree to which HT use provided incremental prediction of the presence versus absence of obstructive CAD over and above available healthy user variables, we performed a logistic regression modeling in three steps. The first step evaluated the unadjusted ORs and 95% CIs of history of HT use in predicting the presence of obstructive CAD. In the second step, we developed a multivariate model of selected lifestyle and risk factor variables. These variables included traditional risk factors (diabetes, chronic disease, functional limitation, aspirin use) as well as those that were associated with either menopausal type or HT use, with a P e 0.05. To avoid overfitting, we included metabolic syndrome and the National Cholesterol Education Program, Adult Treatment Panel III Global Coronary Heart Disease Risk Score that combines several traditional risk factors. This model included all variables listed in Table 5 , with the exception of depression (which was collinear with antidepressant use), menopause, or HT use. In the third step, we added HT use to this model. We then used the log-rank test to estimate the incremental predictive power of HT use over and above that provided by the multivariate model. The same sequence of steps was repeated using a linear regression when the outcome was the continuous log-transformed CAD severity score. In this latter case, we used the F test to estimate the significance of the incremental R 2 obtained when HT was added to the multivariate model.
Unadjusted Kaplan-Meier curves were used to compare event-free survival from CVD events among women with no history of HT use, those who initiated their HT use before age 55 years, and those initiating HT use at age 55 years or more. We then used Cox proportional hazards regression to adjust for important covariates. The proportional hazards assumption of invariant relative risk was tested and found to be satisfactory for all models constructed. For all analyses, a P value of less than 0.05 was considered statistically significant. All analyses were performed using the SAS 9.1 software (SAS Institute, Inc., Cary, NC).
RESULTS
The demographics and clinical profile for the 654 postmenopausal women with complete reproductive hormone variables and coronary angiography results are shown in Table 1 . The women represent a broad age range (36-86 y), 17% were nonwhite (primarily African American), and most had at least one cardiac risk factor. A total of 134 (20%) had undergone surgical menopause. These women were younger than the women with natural menopause (58 vs 63 y, P G 0.0001) and were more than twice as likely to use HT (age-adjusted OR [95% CI], 2.52 [1.59-4.01]).
Menopause, gynecological surgery, and angiographic CAD
Women with angiographic obstructive CAD (n = 167) were older compared with those without obstructive CAD (n = 487). After age adjustment, there were no significant differences between the two groups in age of menopause (Table 2 ). There was an inverse relationship between the presence of obstructive CAD and a history of menopausal symptoms (OR [95% CI], 0.58 [0.40-0.84]) and bilateral oophorectomy before the age of 55 years (0.57 [0.37-0.86]; Table 2 ). Sensitivity analyses using the CAD severity score as the dependent variable demonstrated similar differences (age-adjusted A coefficient [SE] for menopausal symptoms, j4.08 [1.21] ; P = 0.0008; for any gynecological surgery, j3.67 [1.18] ; P = 0.002). Repeat ageadjusted analyses excluding the women with imputed menopause age attenuated the effect of menopausal symptoms (P = 0.19) but not of any gynecological surgery (OR [95% CI], 0.40 [0.26-0.61]; P G 0.0001).
HT use and obstructive CAD
We evaluated the relationships between HT use and obstructive CAD in the total population. After adjustment for age, historical ever users of HT had a significantly lower prevalence of CAD compared with never users (0.41 [0.28-0.60]; Table 3 ). Similarly, women with current HT use were less likely to have obstructive CAD (0.51 [0.34-0.75]). Initiation of HT use at a younger age was marginally associated with a lower prevalence of angiographic CAD in the overall population. Most HT users were taking unopposed estrogen ( Table 3 ). 
HT use in surgical and natural menopause
Women who had undergone surgical menopause were significantly younger than women with natural menopause ( Table 4 ). Compared with women with natural menopause, those with surgical menopause were more than twice as likely to use HT (age-adjusted OR, 2.52 [1.59-4.01]), consisting almost exclusively of unopposed estrogen (Table 4) . Notably, a relatively high proportion of women with natural menopause also used unopposed estrogen, probably related to the relatively high hysterectomy rate ( Table 2 ).
Association of HT use with CAD in surgical and natural menopause
We compared the angiographic CAD severity score across HT subgroups stratified by natural versus surgical menopause ( Fig. 1 ). Among the women with surgical menopause, there was no statistical difference among those who never used HT, those who initiated HT before age 55 years, and those initiating HT after age 55 years (age-adjusted P = 0.12), although there were very few women in the latter group. In contrast, among the women with natural menopause, the overall difference among the three HT subgroups was statistically significant (age-adjusted P = 0.0002). Among the natural menopause subgroups, women initiating HT before age 55 years had significantly lower CAD severity compared with never HT users (age-adjusted A [SE] = j6.23 [1.50], P G 0.0001), whereas those initiating HT after age 55 years did not differ statistically from never HT users (j3.34 [2.13] , P = 0.12). The interaction term between the type of menopause and HT subgroup was significant (P = 0.01), suggesting a differential HT effect by surgical versus natural menopause.
In further sensitivity analyses, we stratified the obstructive CAD results according to no HT use, initiation of HT use before 2 years after menopause, and initiation after 2 years of reaching menopause. This was repeated for 5 and 10 years, according to more recently published thresholds. 14 The P values for the menopause type by HT group interaction term were 0.025, 0.026, and 0.036 for 2-, 5-, and 10-year thresholds, respectively, when the outcome was the presence versus absence of obstructive CAD, and 0.06, 0.07, and 0.07, respectively, when the outcome was the log-transformed CAD severity score. Although the women with natural menopause showed the same relations in angiographic CAD severity across HT groups as shown in Figure 1 (all P values G0.0001), the differences were nonsignificant in the women with surgical menopause (P value range = 0.72-0.91).
Exploration of Bhealthy user[ effects
Initiating HT use before and after age 55 years in women with natural and surgical menopause differed from non-HT users by both traditional and nontraditional risk factors including physical activity, nutritional, and psychosocial variables ( Table 5 ). When the women with natural and surgical menopause were pooled, the HT subgroups (no HT and initiating HT before age 55 y and after age 55 y) showed significant differences in both traditional and nontraditional risk factors that included physical activity and psychosocial variables (Table 5 ). At the time of WISE enrollment, HT users were younger, had a higher income, were less likely to smoke, were less obese, and had a lower Framingham Risk Score; however, they had more frequent depression, lower usage of aspirin, and an earlier onset of menopause (Table 5 ). We used a Bhealthy user[ risk model that included all the factors listed in Table 5 , with the exception of history of depression, which was collinear with antidepressant use, or the menopause status or HT variables such as age at menopause, duration of HT use, and others. Unadjusted, a history of HT use was strongly associated with a lower incidence of CAD (OR [95% CI], 0.34 [0.24-0.48]; P G 0.0001) and explained 8% of the total variance in CAD. When HT use was added to the full Bhealthy user[ model, the OR (95% CI) for HT use was attenuated to 0.44 (0.30-0.73; P = 0.002) and the contribution of HT use to the total variance dropped to 2%, which still provided a statistically significant increment (P = 0.0003) over and above the healthy user model for predicting the presence or absence of CAD. When the outcome was the CAD severity score, history of HT use became nonsignificant when added to the healthy user model (from A [SE] = j6.46 [1.16] , P G 0.0001, to j2.35 [1.36] , P = 0.08).
Association of HT use with adverse CVD events in surgical and natural menopause
After adjustment for age, historical ever users of HT had a trend toward lower incidence of adverse CVD events compared with never users (hazard ratio [95% CI], 0.72 [0.50-1.04)]; P G 0.08). When stratified by surgical versus natural menopause, there was no difference in event rates among the surgical menopause subgroups (P = 0.51) but a significant difference among the natural menopause subgroups (P = 0.012; Fig. 2 ). Parallel to the finding for angiographic CAD, HT use was associated with fewer CVD events in women with natural menopause, with the women initiating HT before 55 years having the lowest CVD event rate.
Because the number of women in the surgical menopause subgroups was relatively low, thus limiting statistical power to detect event differences within this stratum, we collapsed the two HT groups into type of menopause (natural/surgical) and 
DISCUSSION
To our knowledge, our findings represent the first observation evaluating HT use to core laboratory assessment of angiographic CAD and adverse CVD events in women. The current results link HT use with less angiographic CAD events particularly with an earlier onset of HT use. A significant but small residual beneficial association remained even after statistical adjustment for a multitude of variables measured in the WISE study attributable to a Bhealthy user[ effect. HT use and particularly earlier initiation of HT use were also associated with a lower incidence of adverse CVD events. However, this effect became nonsignificant after adjustment for the presence or severity of obstructive CAD. This type of pattern is suggestive of a mediating effect, such that the beneficial association between HT use and reduced CVD event rates seems to be mediated via the mechanism of less atherosclerosis.
The current results further suggest that HT initiated at a relatively early age (G55 y) in natural menopause is associated with a benefit, consistent with recent studies using an intermediate CVD marker in relatively young women, 21, 22 as well as subgroup analyses of the WHI. 14, 23 The current results are also consistent with recent clinical trials that have failed to show a benefit either for angiographic coronary disease 8, 9 FIG. 2. Surgical versus natural menopause, HT, and freedom from major adverse cardiovascular events. Unadjusted Kaplan-Meier curves and P values for natural menopause HT before age 55 years (n = 215), HT after 55 years (n = 61), and no HT (n = 233) as well as surgical menopause HT before age 55 years (n = 96), HT after age 55 years (n = 8), and no HT (n = 28). Major events defined as CVD mortality or nonfatal myocardial infarction, heart failure, or stroke. HT, hormone therapy; CVD, cardiovascular disease. CAD, systolic and diastolic blood pressure, waist circumference, waist-to-hip ratio, prior CAD, lipid-lowering therapy, antihypertensive therapy, anxiolytics, angiotensin-converting enzyme inhibitors, and nitrates. There were significant menopause type Â HT group interaction terms for diabetes (P = 0.01); vitamins C, E, and A (P = 0.04); other chronic disease (P = 0.01); age at menopause (P G 0.0001); and years since menopause (P = 0.04). All other interactions were nonsignificant. P(HT), P values for HT group across the entire sample after adjustment for natural vs surgical menopause and age; P(MP), P value for type of menopause from the same model, after adjustment for HT group and age; BMI, body mass index; DASI, Duke Activity Status Inventory, a measure of functional capacity and physical activity habits; Hx, history of; ATP III Risk, National Cholesterol Education Program, Adult Treatment Panel III Global Coronary Heart Disease Risk Score (see BMethods[); CAD; coronary artery disease; HT, hormone therapy. Chronic disease included diabetes, chronic obstructive pulmonary disease, renal disease, autoimmune disease, anorexia, or 925 drinks/wk. or for cardiac events 10<12 in older women and suggest that the antiatherosclerotic HT effect, if present, may be age dependent.
Early prior observational human studies 3, 18, 21, 22, 24, 25 failed to distinguish premature surgical menopause (removal of ovaries before the time natural menopause would have occurred) from other forms of surgical menopause (hysterectomy or postmenopausal oophorectomy), or separate hysterectomy (cessation of menstrual periods with persistent ovulatory function) from bilateral oophorectomy (cessation of ovulatory function), whereas contemporary studies do not have this failing. 24, 26 Stampfer and Colditz 27 indicated that the magnitude of observed HT protection was greater among those with surgical menopause compared with natural menopause in five of the seven studies that addressed this; however, these data are similarly limited by the failure to accurately define the type of menopause. Notably, our current results, using a specific definition of surgical menopause that includes the age of surgery relative to the age of menopause, are consistent with more recent studies using carotid intima-media thickness, which found no association with HT in women with surgical menopause. 28 Additional studies also failed to find an adverse association between surgical menopause and carotid intima-media thickness, 29 or hysterectomy and future cardiovascular events. 30 Finally, our results are consistent with a prior study that evaluated atherosclerotic heart disease in women defined as having a documented myocardial infarction, positive ischemic stress test, or angina and demonstrated the same prevalence of atherosclerosis among 267 women with bilateral oophorectomy and 385 hysterectomized women. 31 The mechanism(s) behind this apparent differential association between HT use and CAD by surgical versus natural menopause is unknown. Because HT use after surgical menopause was routinely prescribed, we had very few women in the surgical menopause group with either HT initiation after 55 years or non-HT use. Thus, limited statistical power is potentially a leading explanation for the lack of association of HT use in women with surgical menopause. It is also possible that the residual beneficial HT association observed in women with natural menopause can be explained by unadjusted additional healthy user variables (residual confounding), for example, prescribing physician decision making. Alternatively, physiological differences between surgical and natural menopause may account for these findings. Surgical oophorectomy, for example, reduces both blood estrogens and androgens compared with natural menopause in which the ovaries continue to produce androgens that are converted to estrogens in peripheral tissue, 32 with a resulting endogenous estrogen and androgen hormonal milieu that may shape a differential HT response. Bilateral oophorectomy is performed for a variety of reasons in humans, including polycystic ovary syndrome where oophorectomy might theoretically lower subsequent CAD risk. Our results demonstrating a lower angiography CAD severity score in our surgical menopause non-HT users compared with the natural menopause non-HT users support this possibility. Finally, these results suggest that animal oophorectomy-HT models may not accurately reflect human physiology. 2, 5, 33, 34 Limitations
The current study results are limited by the observational design that precludes the determination of causality. Our results obtained from a population of women undergoing coronary angiography for suspected ischemia may not be generalizable to a healthy population with regard to referral bias because of cardiac risk factor status. Statistical power to detect relations between HT use, CAD, and adverse CVD events in our women with surgical menopause was limited, because of the low prevalence of no HT use in this group. Moreover, it is inherently difficult to pinpoint the age of onset of HT use and duration of HT therapy that rely on participant recollection. A larger data set with a greater distribution of HT duration in early and late users could help further evaluate this. Also, the cross-sectional component of our study design is unable to detect early adverse cardiac events due to HT, as have been observed in prospective, randomized trials. 10, 12 Finally, our choice of the age cutpoint for initiating HT use of 55 years may be questioned. This age was chosen because this is the age at which 95% of the population has reached menopause. In subsequent sensitivity analyses (reported above), we looked at other possible cutpoints that yielded very similar results, suggesting that the distinction between earlier versus later HT initiation is robust and not dependent on the specific age selected.
CONCLUSIONS
Recent HT trials 8<12 have consistently demonstrated overall no benefit and early adverse effects in older postmenopausal women and have questioned the validity of the prior animal 2,5 and human epidemiological results. 5<7 The current study results combined with recent publications evaluating younger women and early onset of HT use 13<15 suggest that the beneficial association between HT and CAD in women with natural menopause observed in prior studies is attributable to both a Bhealthy user[ effect and a residual antiatherosclerotic effect, particularly among those starting HT at a relatively earlier age (G55 y). Because menopausal symptoms requiring treatment remain common, 35 further investigation to document the presence or absence of these putative antiatherosclerotic benefits, as well as to improve the safety of HT regimens, is clearly warranted. The current analysis sheds light on prior data discrepancies and may be useful for prospective HT clinical trial planning.
